The international chronic myelomonocytic leukemia (CMML) treatment market is witnessing a period of rapid growth. This development can be attributed to several factors, such as the increasing incidence of CMML, advancements in care, and increasing awareness about the disease. The market is marked by a wide range of portfolio of therapies available,